Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19
A reduction in the risk of early death or respiratory failure at day 28 of 45% in the Intent-To-Treat (ITT)...